Praxis Precision Medicines Highlights Major Epilepsy Advances
BOSTON – Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders, is gearing up for an important presentation at the International Epilepsy Congress (IEC) scheduled in Lisbon. This gathering is set to take place soon, where Praxis will showcase the promising topline results from the RADIANT study focused on focal onset seizures (FOS) and share significant updates on its precision epilepsy pipeline.
Presentations at the Congress
During the IEC, Praxis will host around twelve presentations, revealing the latest preclinical and clinical data derived from its extensive research efforts. This reflects the company’s commitment to advancing treatment methodologies and paradigms in epilepsy:
Vormatrigine Developments
The presentations will include insights about Vormatrigine, presenting positive topline results from the RADIANT study, updates from a first-in-human Phase 1 study, and progress on the POWER1 pivotal study aimed at transforming treatment landscapes for epilepsy. The preliminary findings demonstrate exceptional promise for Vormatrigine in addressing FOS.
Advancements with Relutrigine
Additionally, Praxis will discuss its promising drug candidate Relutrigine, with crucial information coming from the EMBOLD study focused on SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs). Through these findings, they emphasize the potential of Relutrigine in addressing significant unmet medical needs across a broad spectrum of epilepsy disorders.
Elsunersen Ongoing Studies
Furthermore, Praxis will provide updates on Elsunersen, highlighting data from the ongoing EMBRAVE3 registrational study. The global emergency use cases suggest long-term benefits and safety for patients with early onset SCN2A gain-of-function DEE, showcasing the potential of precision sodium channel modulation to further enhance patient outcomes.
Engaging with the Epilepsy Community
Praxis acknowledges the importance of this congress, as noted by its Chief Scientific Officer, Steven Petrou. He expressed enthusiasm about sharing their advancements with both clinical practitioners and patient advocacy groups in attendance. Emphasizing their patient-centered approach to epilepsy treatment, the company seeks to shed light on how their studies can translate into meaningful therapies for individuals suffering from epilepsy.
Booth Interaction and Opportunities
The presence of Praxis at Booth #435 will allow attendees to engage directly with the research team and explore how the company is committed to delivering impactful, patient-oriented outcomes through their proprietary platforms. By participating in scientific presentations, they plan to foster discussions on their groundbreaking approach and exemplary progress.
Key Presentation Details
As part of this significant event, Praxis has scheduled:
Platform Presentation
On Sunday, experts from Praxis will present a platform discussion from 15:15 to 16:15 PM (CET) at Aud V (Pavilion 1), regarding the predictive validity of preclinical seizure models in generalized epilepsies. This session aims to provide insights into the efficacy of their lead candidates.
Poster Presentations
In-person poster sessions will illuminate vital findings, including:
- P196: Vormatrigine’s efficacy from the RADIANT Open Label Phase 2 Study.
- P157: Relutrigine’s positive impact demonstrated through the EMBOLD study.
- P158: Utilizing Relutrigine in emergency cases for SCN2A-DEE.
- P504: Treatment advancements in early onset SCN2A encephalopathy.
- P635: Empowering patient journey insights through observational studies.
A Look at Praxis Precision Medicines
Praxis Precision Medicines stands at the forefront of biopharmaceutical innovation, working diligently on therapies designed to restore balance in neuronal excitation and inhibition. Leveraging genetic insights into the development of treatments for neurological disorders, their proprietary platforms Cerebrum™ and Solidus™ aim to revolutionize how epilepsy and related conditions are treated. With a diversified portfolio, Praxis is committed to pushing boundaries in the CNS domain through evident medical breakthroughs.
Frequently Asked Questions
What is the significance of the International Epilepsy Congress?
The IEC is a global gathering of professionals in the epilepsy community, fostering collaboration and knowledge sharing about advancements in epilepsy research and treatment.
What presentations can we expect from Praxis?
Praxis will share updates on their RADIANT study, Vormatrigine, Relutrigine, and Elsunersen, showcasing new findings that could enhance epilepsy treatments.
Who can benefit from the findings shared at the congress?
Patients living with epilepsy, healthcare providers, researchers, and advocacy groups can benefit from the insights shared by Praxis, emphasizing advancements in patient-centered care.
What is Vormatrigine's role in epilepsy treatment?
Vormatrigine is being developed as a leading treatment option for FOS, demonstrating robust efficacy in ongoing clinical studies.
How does Praxis contribute to epilepsy research?
By focusing on genetic insights and patient-centered approaches, Praxis strives to create novel therapies aimed at addressing unmet needs in the epilepsy landscape.
